Regeneron Pharmaceuticals is a biotech company headquartered in New York. While it works on a number of drugs and diseases, it's most recently been in the news for REGN-COV2 — the experimental antibody cocktail.
The antibody cocktail is being studied as a possible treatment for the novel coronavirus.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Open | $1,070.75 |
|---|---|
| High | $1,102.95 |
| Low | $1,068.06 |
| Close | $1,088.81 |
| Previous close | $1,060.86 |
| Change | $27.95 |
| Change % | 2.6342% |
| Volume | 121,895 |
| 52-week range | $721.51 - $1,106.16 |
|---|---|
| 50-day moving average | $1,023.27 |
| 200-day moving average | $928.85 |
| Wall St. target price | $1,077.22 |
| PE ratio | 31.5288 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $33.83 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1088.805 from 2024-07-24
| 1 week (2024-07-18) | 2.02% |
|---|---|
| 1 month (2024-06-25) | 1.64% |
| 3 months (2024-04-25) | 22.24% |
| 6 months (2024-01-25) | 14.75% |
| 1 year (2023-07-25) | 49.18% |
|---|---|
| 2 years (2022-07-25) | 85.40% |
| 3 years (2021-07-25) | 84.76% |
| 5 years (2019-07-25) | 258.84% |
Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, Regeneron Pharmaceuticals shares trade at around 32x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4591. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.4 billion.
The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $13.1 billion |
|---|---|
| Operating margin TTM | 24.12% |
| Gross profit TTM | $7 billion |
| Return on assets TTM | 7.74% |
| Return on equity TTM | 15.28% |
| Profit margin | 29.45% |
| Book value | $250.15 |
| Market Capitalization | $117.5 billion |
TTM: trailing 12 months
We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as $721.51 up to $1106.16. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.128. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.